
BCMA-Targeting CAR T-Cell Therapy Is Feasible in Patients With Multiple Myeloma and CNS Involvement
Chimeric antigen receptor (CAR) T-cell therapy is safe and feasible in patients with relapsed, refractory multiple myeloma (RRMM) with central nervous system (CNS) involvement, according to study results published in Blood Advances. The researchers …